Design, Synthesis, In Vitro Evaluation, Multitargeted Molecular Docking, and In Silico Analysis of Some Azo-Linked 1,3,4-Thiadiazole and 1,2,4-Triazole Heterocyclic Hybrids as Potent Antitubercular Agents

设计、合成、体外评价、多靶点分子对接和计算机分析一些偶氮连接的1,3,4-噻二唑和1,2,4-三唑杂环化合物作为强效抗结核药物

阅读:2

Abstract

The swift emergence of multidrug- and highly drug-resistant strains of Mycobacterium tuberculosis (Mtb) makes it essential to develop new agents with varied chemical structures and multitarget mechanisms of action. In the current investigation, we have designed and synthesized 24 novel heterocyclic ring-substituted 1,3,4-thiadiazole (5a-l) and 1,2,4-triazole (6a-l) hybrids to be tested against the H37RV strain of M. tuberculosis. Compounds 5b, 5d, 5e, 5f, 6b, 6c, 6d, and 6f showed good to moderate effectiveness against tuberculosis, with minimum inhibitory concentration (MIC) values ranging from 4 to 64 μg/mL. Compounds 5b and 6b display an MIC value of 4 μg/mL, suggesting significant antitubercular potential and warranting further exploration as effective antitubercular agents. The chemical structures of the synthesized compounds were determined through spectral techniques (Fourier transform infrared (FT-IR), NMR {(1)H, (13)C}, and mass spectroscopy). The molecular docking analysis shows that these compounds can successfully bind to the active site of the five most promising proteins for treating tuberculosis. ADME-T, molecular dynamics (MD) simulation, and Density Functional Theory (DFT) analysis confirm that these compounds have good drug-like properties and remain stable in the binding sites of the selected target proteins. We assessed the cytotoxicity of the chosen compounds. According to the findings, this research thoroughly indicated that these newly created derivatives could serve as promising and effective multitargeted antitubercular agents.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。